Work

From Hit to Lead: Discovery of Novel Selective RIPK1 Inhibitor with Pyridoimidazole Scaffold for the Treatment of Autoimmune Diseases through Phenotypic Screening and Structural Optimization

Year: 2026

Type: article

Source: Journal of Medicinal Chemistry

DOI: 10.1021/acs.jmedchem.5c03145

Institutions: Fudan University, Pudong Medical Center, Chinese Academy of Sciences, Shanghai University of Traditional Chinese Medicine, Shanghai Institute of Materia Medica, State Key Laboratory of Drug Research, Shuguang Hospital, Zhengzhou University, Xuzhou Medical College

Language: English

Topic: Cell death mechanisms and regulation

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: National Natural Science Foundation of China, Xuzhou Medical University

Awards: G1477281098, G2519089350, G5508054775, G7039745317

OpenAlex ID: W7127076504

FWCI:

Cites: 64

Cited by:

Related to: